한글목차

만성 신장 질환 치료 세계 시장 규모는 2024년 354억 달러로 평가되며, 2030년까지 CAGR 4.70%로 예측 기간 동안 꾸준히 성장할 것으로 예상됩니다.

세계 만성 신장 질환(CKD) 치료 시장은 광범위한 의료 산업의 중요한 구성요소로, CKD로 고통받는 환자를 관리하고 삶의 질을 개선하기 위한 다양한 의료 개입, 치료 및 약물을 포함하며, CKD는 진행성 질환으로 무증상인 경우가 많으며, 방치할 경우 신부전으로 이어질 수 있습니다. 따라서 CKD 치료 시장은 전 세계 건강 문제를 해결하는 데 있어 매우 중요한 역할을 하고 있습니다.

시장 촉진요인

만성 신장 질환(CKD) 및 관련 동반 질환의 유병률 상승

주요 시장 과제

경제적 장벽과 의료 격차

주요 시장 동향

맞춤의료와 정밀의료

목차

제1장 개요

제2장 조사 방법

제3장 주요 요약

제4장 고객의 소리

제5장 세계의 만성 신장 질환 치료 시장 전망

• 시장 규모 및 예측
  • 금액별
• 시장 점유율과 예측
  • 제품 유형별(진단, 치료, 투석, 기타)
  • 최종사용자별(병원, 진단 실험실, 기타)
  • 지역별
  • 기업별(2024년)
• 시장 맵

제6장 북미의 만성 신장 질환 치료 시장 전망

• 시장 규모 및 예측
• 시장 점유율과 예측
• 북미 : 국가별 분석
  • 캐나다
  • 멕시코

제7장 유럽의 만성 신장 질환 치료 시장 전망

• 시장 규모 및 예측
• 시장 점유율과 예측
• 유럽 : 국가별 분석
  • 영국
  • 이탈리아
  • 프랑스
  • 스페인

제8장 아시아태평양의 만성 신장 질환 치료 시장 전망

• 시장 규모 및 예측
• 시장 점유율과 예측
• 국가별
• 아시아태평양 : 국가별 분석
  • 인도
  • 일본
  • 한국
  • 호주

제9장 남미의 만성 신장 질환 치료 시장 전망

• 시장 규모 및 예측
• 시장 점유율과 예측
• 남미 : 국가별 분석
  • 아르헨티나
  • 콜롬비아

제10장 중동 및 아프리카의 만성 신장 질환 치료 시장 전망

• 시장 규모 및 예측
• 시장 점유율과 예측
• 중동 및 아프리카 : 국가별 분석
  • 사우디아라비아
  • 아랍에미리트

제11장 시장 역학

• 성장 촉진요인
• 과제

제12장 시장 동향과 발전

• 제품 출시
• 인수합병

제13장 세계의 만성 신장 질환 치료 시장 : SWOT 분석

제14장 경쟁 구도

• AbbVie Inc.
• Amgen Inc.
• Bayer AG
• Bristol-Myers Squibb Company
• F. Hoffmann-La Roche Ltd
• GlaxoSmithKline PLC
• Merck & Co. Inc.
• Pfizer Inc.
• Sysmex Corporation
• Teva Pharmaceutical Industries Ltd.

제15장 전략적 제안

제16장 조사 회사 소개 및 면책사항

영문목차

Global Chronic Kidney Disease Treatment Market was valued at USD 35.40 Billion in 2024 and is anticipated to project steady growth in the forecast period with a CAGR of 4.70% through 2030. The Global Chronic Kidney Disease (CKD) Treatment Market is a critical component of the broader healthcare industry, encompassing a wide range of medical interventions, therapies, and medications aimed at managing and improving the quality of life for individuals affected by CKD. CKD is a progressive and often asymptomatic condition that can lead to kidney failure if left untreated. As such, the CKD Treatment Market plays a pivotal role in addressing this global health concern.

Key Market Drivers

Rising Prevalence of Chronic Kidney Disease (CKD) and Related Comorbidities

The increasing global prevalence of Chronic Kidney Disease (CKD) is a fundamental driver of the Global CKD Treatment Market, as it directly fuels demand for pharmaceuticals, dialysis services, renal replacement therapies, and specialized healthcare services. This rising disease burden is largely attributed to several interconnected factors, including aging populations, lifestyle-related disorders, and genetic predispositions. Chronic Kidney Disease is a progressive and irreversible condition that affects millions worldwide. The 2023 ISN-GKHA multinational study on the global burden of kidney disease reports that approximately 850 million people worldwide are affected by Chronic Kidney Disease (CKD). The findings highlight that CKD impacts individuals across all age groups and racial backgrounds, with a disproportionately higher prevalence among economically disadvantaged populations. These insights emphasize the urgent need for targeted healthcare policies, improved access to early diagnosis, and expanded treatment infrastructure, particularly in high-risk and underserved communities, with a significant portion of cases remaining undiagnosed until the later stages. This expanding patient population is a major catalyst for the growth of the CKD treatment market. Improved screening programs and awareness campaigns are leading to earlier diagnoses, increasing demand for medications and lifestyle management interventions. Among patients without proteinuria data, the CKD diagnosis rate was 5.9%, with a significantly lower rate of 2.9% in stage G2. In contrast, for patients with quantitative proteinuria test results, the diagnosis rates were 43.5% overall and 31.3% in stage G2. These findings underscore the critical role of quantitative proteinuria testing in early CKD detection, highlighting a significant gap in diagnosis rates when such data is unavailable. This reinforces the need for wider adoption of advanced diagnostic protocols to improve CKD identification and clinical decision-making.

Key Market Challenges

Economic Barriers and Healthcare Disparities

One of the primary challenges is the economic disparity that exists globally. Access to advanced CKD treatments and medications often requires significant financial resources. High healthcare costs, including expenses related to dialysis, transplantation, and specialized medications, can be prohibitive for individuals with limited financial means.

In many regions, healthcare coverage and insurance options may not adequately address CKD treatment costs. Patients without comprehensive insurance may face difficulties in accessing essential treatments, which can lead to delayed or suboptimal care. Vulnerable populations, such as low-income individuals and underserved communities, are disproportionately affected by economic barriers. This can result in delayed CKD diagnosis, limited access to specialized care, and poorer outcomes.

Key Market Trends

Personalized Medicine and Precision Care

Personalized medicine is gaining prominence in the CKD treatment market. Healthcare providers are increasingly customizing treatment plans to meet the specific needs of individual CKD patients. This approach takes into account factors such as the patient's stage of CKD, comorbidities, genetic factors, and response to previous treatments.

Biomarker research plays a crucial role in personalizing CKD treatment. Biomarkers, such as specific proteins or genetic markers, are used to predict disease progression and treatment efficacy. This trend enables healthcare professionals to make more informed decisions about treatment strategies, including medication selection and dosing. Advances in genomics are revolutionizing CKD care. Genetic testing can identify genetic mutations or predispositions that influence CKD risk and progression. This information allows for the development of targeted therapies and interventions, with the potential to slow or halt disease progression in individuals with specific genetic profiles.

Key Market Players

• AbbVie Inc.
• Amgen Inc.
• Bayer AG
• Bristol-Myers Squibb Company
• F. Hoffmann-La Roche Ltd
• GlaxoSmithKline PLC
• Merck & Co. Inc.
• Pfizer Inc.
• Sysmex Corporation
• Teva Pharmaceutical Industries Ltd

Report Scope:

In this report, the Global Chronic Kidney Disease Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Chronic Kidney Disease Treatment Market, By Product Type:

• Diagnosis
• Treatment
• Dialysis
• Others

Chronic Kidney Disease Treatment Market, By End User:

• Hospitals
• Diagnostic Laboratories
• Others

Chronic Kidney Disease Treatment Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Chronic Kidney Disease Treatment Market.

Available Customizations:

Global Chronic Kidney Disease Treatment market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Chronic Kidney Disease Treatment Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Product Type (Diagnosis, Treatment, Dialysis, Others)
  • 5.2.2. By End User (Hospital, Diagnostic Laboratories, Other)
  • 5.2.3. By Region
  • 5.2.4. By Company (2024)
• 5.3. Market Map

6. North America Chronic Kidney Disease Treatment Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Product Type
  • 6.2.2. By End User
  • 6.2.3. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Chronic Kidney Disease Treatment Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Product Type
      • 6.3.1.2.2. By End User
  • 6.3.2. Canada Chronic Kidney Disease Treatment Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Product Type
      • 6.3.2.2.2. By End User
  • 6.3.3. Mexico Chronic Kidney Disease Treatment Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Product Type
      • 6.3.3.2.2. By End User

7. Europe Chronic Kidney Disease Treatment Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Product Type
  • 7.2.2. By End User
  • 7.2.3. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Chronic Kidney Disease Treatment Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Product Type
      • 7.3.1.2.2. By End User
  • 7.3.2. United Kingdom Chronic Kidney Disease Treatment Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Product Type
      • 7.3.2.2.2. By End User
  • 7.3.3. Italy Chronic Kidney Disease Treatment Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Product Type
      • 7.3.3.2.2. By End User
  • 7.3.4. France Chronic Kidney Disease Treatment Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Product Type
      • 7.3.4.2.2. By End User
  • 7.3.5. Spain Chronic Kidney Disease Treatment Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Product Type
      • 7.3.5.2.2. By End User

8. Asia-Pacific Chronic Kidney Disease Treatment Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Product Type
  • 8.2.2. By End User
• 8.2.3 By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Chronic Kidney Disease Treatment Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Product Type
      • 8.3.1.2.2. By End User
  • 8.3.2. India Chronic Kidney Disease Treatment Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Product Type
      • 8.3.2.2.2. By End User
  • 8.3.3. Japan Chronic Kidney Disease Treatment Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Product Type
      • 8.3.3.2.2. By End User
  • 8.3.4. South Korea Chronic Kidney Disease Treatment Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Product Type
      • 8.3.4.2.2. By End User
  • 8.3.5. Australia Chronic Kidney Disease Treatment Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Product Type
      • 8.3.5.2.2. By End User

9. South America Chronic Kidney Disease Treatment Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Product Type
  • 9.2.2. By End User
  • 9.2.3. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Chronic Kidney Disease Treatment Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Product Type
      • 9.3.1.2.2. By End User
  • 9.3.2. Argentina Chronic Kidney Disease Treatment Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Product Type
      • 9.3.2.2.2. By End User
  • 9.3.3. Colombia Chronic Kidney Disease Treatment Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Product Type
      • 9.3.3.2.2. By End User

10. Middle East and Africa Chronic Kidney Disease Treatment Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Product Type
  • 10.2.2. By End User
  • 10.2.3. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Chronic Kidney Disease Treatment Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Product Type
      • 10.3.1.2.2. By End User
  • 10.3.2. Saudi Arabia Chronic Kidney Disease Treatment Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Product Type
      • 10.3.2.2.2. By End User
  • 10.3.3. UAE Chronic Kidney Disease Treatment Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Product Type
      • 10.3.3.2.2. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Developments
• 12.2. Product Launches
• 12.3. Mergers & Acquisitions

13. Global Chronic Kidney Disease Treatment Market: SWOT Analysis

14. Competitive Landscape

• 14.1. AbbVie Inc.
  • 14.1.1. Business Overview
  • 14.1.2. Product & Service Offerings
  • 14.1.3. Recent Developments
  • 14.1.4. Financials (If Listed)
  • 14.1.5. Key Personnel
  • 14.1.6. SWOT Analysis
• 14.2. Amgen Inc.
• 14.3. Bayer AG
• 14.4. Bristol-Myers Squibb Company
• 14.5. F. Hoffmann-La Roche Ltd
• 14.6. GlaxoSmithKline PLC
• 14.7. Merck & Co. Inc.
• 14.8. Pfizer Inc.
• 14.9. Sysmex Corporation
• 14.10. Teva Pharmaceutical Industries Ltd.

15. Strategic Recommendations

16. About Us & Disclaimer